3 growth shares I'd buy with $10,000 today

Sirtex Medical Limited (ASX:SRX) remains an exciting long-term growth prospect.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

When it comes to investing you can't ask for anything more than capital gains with perhaps a little dividend income along the way. Unfortunately, finding the kind of businesses that are likely to deliver both over the long term is no easy task. However, it's not impossible, with some of the more under-the-radar ASX companies offering the best opportunity to deliver handsome returns to smart investors.

Below I have three growth picks I would buy with $10,000 today.

Mitula Group Ltd (ASX: MUA) is an up-and-coming global website operator that aggregates third-party classifieds adverts on its own websites to help boost their visitor numbers. It's primarily a global company that is superbly leveraged to the growth of a digital economy that is heavily outpacing wider global economic growth. The business is profitable with a healthy balance sheet and shares are on an attractive valuation at $1.09 for investors after growth at a reasonable price.

ResMed Inc. (CHESS) (ASX: RMD) is the sleep treatment global medical device company that is also increasingly moving into the digital health and health software-as-a-service space. The company's market-leading products and global horizons have delivered bulletproof like quarter-on-quarter revenue growth. Family run with a long-term focus, I think the ASX-listed scrip at $8.62 looks good value for growth-oriented investors after some overseas exposure.

Sirtex Medical Limited (ASX: SRX) is another global healthcare specialist that is growing sales and profits at consistent double-digit rates thanks to the growing awareness of its SIR-Spheres specialist cancer treatment. The company grew dose sales by 16.7% in financial year 2016 and has forecast another year of double-digit sales growth with several clinical trials in progress that are aimed at promoting further use of its products by oncologists. The shares sells for $30.90, which looks a reasonable price given the potential for the company to keep growing strongly for the next five years and beyond.

Motley Fool contributor Tom Richardson owns shares of ResMed Inc. and Sirtex Medical Limited. You can find Tom on Twitter @tommyr345 The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »